Active substances: Norfloxacin
Satisfactory treatment efficacy and tolerability can be provided by novel DAAs. Certain hard-to-cure populations are prone to have inferior treatment responses, including patients with severe liver decompensation, active hepatocellular carcinoma HCC, and hepatitis C virus HCV genotype 3 HCV-3 infection and those who experience multiple DAA treatment failures.
Benhamou, Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis, Hepatology 2 J.
Mastai. Bruix. Gaya. Rigau et al. Bermann.
Patrick et al. Lui.
Stanley. Forrest. Jalan.
Hislop. Mills et al.
Ferayorni. Grace et al.
Morillas. Cabre. Galan.